Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DJQ8 | ISIN: FR0014008VX5 | Ticker-Symbol: 940
Tradegate
13.05.26 | 19:25
1,492 Euro
+2,19 % +0,032
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
EUROAPI SAS Chart 1 Jahr
5-Tage-Chart
EUROAPI SAS 5-Tage-Chart
RealtimeGeldBriefZeit
1,4821,49421:18
1,4801,49421:00

Aktuelle News zur EUROAPI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17:48EUROAPI statement regarding the Brindisi site70Press Release Paris - May 13, 2026 - EUROAPI takes note of local media reports regarding its Brindisi site. As previously communicated, the review of strategic options for certain industrial assets...
► Artikel lesen
EUROAPI Aktie jetzt für 0€ handeln
29.04.Euroapi: Availabilty of 2026 AGM preparatory documents14
27.03.EUROAPI - Availability of the 2025 Universal Registration Document32
03.03.Euroapi: 2025 results: Core EBITDA margin improved despite sales headwinds, driven by strong cost discipline1.011Press Release Paris, 3rd March, 2026 Progress against FOCUS-27 in a deteriorating environment Accelerated transformation to strengthen the operating model Full-year 2025 results €848.2 million...
► Artikel lesen
16.12.25Euroapi: Market update797Press Release Paris - December 16, 2025 - EUROAPI announced today that its main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend further the duration of their lock-up until December...
► Artikel lesen
10.12.25Euroapi: Tristan Imbert co-opted as Independent Director28
23.10.25Abolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European Sovereignty641As part of the Important Project of Common European Interest (IPCEI) in the field of healthcare, the Med4Cure program includes public support of up to €140 million under France 2030. Abolis...
► Artikel lesen
23.10.25With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty277Press Release The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation...
► Artikel lesen
30.09.25Euroapi: Change in Board's Composition356Press Release Paris - September 30, 2025 - EUROAPI today announces that, in line with best governance's practices, and following his appointment as Recipharm's Chief Financial Officer, effective...
► Artikel lesen
29.07.25Euroapi: First-half 2025 results795Press Release Paris, 29th July 2025 7% to 9% 2025 Core EBITDA margin guidance reaffirmed, with ambition to be in the upper part of the range, supported by thorough execution of the FOCUS-27 plan,...
► Artikel lesen
30.06.25EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan846Press Release Paris - June 30, 2025 - EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing...
► Artikel lesen
04.06.25Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities450Paris - June 4, 2025 - EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,12